27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
The theta/alpha ratio is a promising but specification-dependent marker of cognitive impairment, contingent particularly on ICA and spectral power quantification. 4 key findings →
Participants: 49 Evidence: low
Full summary, score breakdown and related studies → Original source
Face processing abilities are critical for social interaction, yet impairments are common across dementia syndromes and constitute a core diagnostic feature of some neurocognitive disorders. 5 key findings →
Design: systematic review Participants: 3,810 Evidence: high
Full summary, score breakdown and related studies → Original source
Frontotemporal lobar degeneration (FTLD) is a common cause of early-onset dementias marked by progressive declines in behavior, cognition, and/or movement. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Only the reliability half of that contrast is individually significant. 2 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source
Structured Abstract INTRODUCTION Tau pathology typically occurs in Alzheimeŕs disease (AD), however is also frequently present in Parkinsońs disease dementia (PDD) and Dementia with Lewy Bodies (DLB), yet its disease-specific signature is unclear. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The amyloid precursor protein (APP) is heavily studied as the source of amyloid beta in Alzheimer’s disease (AD), however, the complex functions of APP remain poorly understood, as does the impact of APP dosage on neurodevelopment. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Adults with Down syndrome (DS) develop Alzheimer’s disease (AD) brain pathology by age 40 due to triplication of the Amyloid Precursor Protein ( APP ) gene on chromosome 21. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Late-onset unexplained epilepsy is a potential harbinger of dementia, likely driven by network hyperexcitability that facilitates amyloid-β release and tau propagation. 3 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Dysregulated expression and activity of DYRK1A, dual specificity tyrosine phosphorylation regulated kinase 1A, is a feature of several neurodevelopmental and neurodegenerative diseases, including Down syndrome, DYRK1A syndrome, autism spectrum disorders, Alzheimer’s disease, and Parkinson’s disease. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Structured Abstract INTRODUCTION Adults with Down syndrome (DS) have a higher risk of developing Alzheimer’s disease (AD). 3 key findings →
Participants: 58 Evidence: low
Full summary, score breakdown and related studies → Original source
Down syndrome (DS), caused by trisomy 21, confers a near-universal risk for Alzheimer’s disease (AD), yet individuals exhibit marked variability in cognitive decline, suggesting the presence of cellular mechanisms that modulate vulnerability and resilience. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Amyloid plaques contain numerous proteins in addition to amyloid beta in Alzheimer’s disease (AD). 4 key findings →
Participants: 240 Evidence: low
Full summary, score breakdown and related studies → Original source
Among 10,489 participants with incident MCI, the mean age at the incident MCI wave was 70.6 years (SD = 11.53), and 56.6% were female. 5 key findings →
Design: cohort study Participants: 10,489 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Approximately 90% of Parkinson's disease (PD) patients exhibit olfactory deficits, which often precedes motor symptoms by years, and are a robust predictor for PD and subsequent cognitive decline. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Among 1,231 patients (87.2% women; mean age 46.0 ± 13.7 years; 71.5% chronic migraine), 1,175/1,231 (95.5%) endorsed cognitive symptoms, with a mean Mig-SCog total score of 8.2 ± 4.8. 5 key findings →
Design: cross-sectional Participants: 661 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Isolated rapid eye movement sleep behaviour disorder (iRBD) strongly predicts future Lewy body disease and identifies a more aggressive, non-motor phenotype in Parkinson’s disease (PD). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Magnetic resonance imaging (MRI) of the brain routinely combines complementary contrasts—including T1-weighted (T1w), T2-weighted (T2w) and FLAIR sequences—to capture anatomy and pathology. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Aging muscle showed increased inflammatory, extracellular-matrix, and stromal communication programs. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This study aimed to address these limitations by examining whether multilingual experience is associated with longitudinal ageing trajectories across objective and subjective measures spanning cognitive, affective, linguistic, and non-linguistic domains. 5 key findings →
Design: cross-sectional Participants: 193 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Parkinson’s disease (PD) exhibits considerable variability in symptom onset, severity, and clinical trajectories, making prediction of individual disease progression a complex challenge. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The neurodegenerative processes underlying Alzheimer’s disease and related dementias (ADRD) begin years before clinical diagnosis, motivating scalable approaches for earlier identification. 3 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
We introduce Dementia Language Models (DeLMs) – generalizable and controllable representations of cognitive impairment through language – alongside an evaluation framework for establishing their validity and clinical grounding. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Older adults with mild cognitive impairment (MCI) or dementia have elevated fall risk, but fall-related psychological outcomes represent distinct constructs that should not be pooled indiscriminately. 5 key findings →
Participants: 327 Evidence: high
Full summary, score breakdown and related studies → Original source
Performance variability precedes measurable linear decline across PD-risk stratified groups. 4 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Fairness in clinical machine-learning (ML) remains a critical challenge, particularly in neurodegenerative disease where demographic factors may confound disease-related patterns. 1 key finding →
Participants: 757 Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →